Home » News » Life Sciences & Healthcare

Life Sciences & Healthcare

Labor Government’s Flagship $15b Manufacturing Fund Passes into Law

March 30th, 2023

Leading up to the 2022 federal election, the (then) Opposition Leader Anthony Albanese pledged in early 2022 that he would use Labor’s proposed $15 billion National Reconstruction Fund (NRF) to make medical technology, local manufacturing and other critical industry investments a top priority. After some debate in recent months, The National Reconstruction Fund (NRF) Corporation bill was passed by both houses earlier this week with support from the Greens and a number of crossbenchers, after a series of amendments were approved. The […]

Read More

Neuren Pharmaceuticals becomes another Australian Biotech Success Story after US FDA Approves Treatment for Rett Syndrome

March 16th, 2023

Victorian based Neuren Pharmaceuticals’ North American partner, Acadia Pharmaceuticals, has received news this week that its treatment for Rett syndrome was approved by the US Food and Drug Administration. Neuren Pharmaceuticals and Acadia Pharmaceuticals had previously entered an exclusive licence in 2018 to develop and commercialise trofinetide for the treatment of Rett syndrome and other indications. Trofinetide, to be sold under the brand name DAYBUE, is now the first drug to be approved for the treatment of the neurodevelopmental disorder […]

Read More

Telix Pharmaceuticals becomes Australian Biotech Success Story after being one of largest Refundable R&D Tax Offset Recipients

August 15th, 2022

Melbourne-based Telix Pharmaceuticals has been one of the largest recipients of the R&D Tax incentive, and has now achieved a rare feat in Biotechnology;  commercialising a product, and continuing to grow. The company reportedly received a more than $12M R&D tax offset refund for activity undertaken during the year ended 31 December 2020, and more than $11M in the preceding period, for their work on cancer diagnostic and treatment. Telix Pharmaceuticals’ technology uses radio pharmaceuticals to travel through the blood […]

Read More

Paradigm Biopharmaceuticals (ASX:PAR) Received $8.2m R&D Tax Refund

June 13th, 2022

Melbourne based Paradigm Biopharmaceuticals has reported receipt of a $8.2 million research and development tax incentive refund for the YE 30 June 2021 relating to ongoing R&D activities into its pentosan polysulfate sodium treatment. The company has advised that the funds will be reinvested in R&D activities and to support its global Phase 3 and Phase 2 clinical programs. Paradigm Biopharmaceuticals’ R&D offset refund is one of the larger R&D tax offsets reported, alongside the likes of Telix Pharmaceuticals’ R&D […]

Read More

Categories

Archives